Search Results

Aluna, the award-winning lung health management platform, announced it has completed a $15.3 million Series B round of financing to continue growing its solution among doctors and patients managing asthma, cystic fibrosis and COPD.

Regard (formerly known as HealthTensor), a software company developing an artificial intelligence (AI) co-pilot for physicians to help diagnose medical conditions, today announced it has raised $15.3 million in Series A funding.

The global stool softener market size was USD 1.53 Billion in 2021 and is expected to register a revenue CAGR of 7.15% during the forecast period, according to latest analysis by Emergen Research.

According to Vision Research Reports, the global Healthcare ERP Market size is expected to worth around US$ 15.3 billion by 2030 and is projected to grow at a CAGR of 8.6% during forecast period 2021 to 2030.

Kuros Biosciences, a leader in next-generation bone graft technologies, announced financial results for full year 2023 along with continued significant growth.

Meridian Bioscience, Inc and SD Biosensor, Inc. (“SDB”) (KOSE: A137310) and SJL Partners LLC (“SJL”) (collectively, the “Consortium”) announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.

Tthe National Institute for Innovation in Manufacturing Biopharmaceuticals confirms that it has received $153M in new funding from the National Institute of Standards and Technology as announced by U.S. Commerce Secretary Gina Raimondo at NIIMBL’s National Meeting in Washington, DC.

Evidation Health today announced the close of $153 million in Series E growth funding to rapidly expand its virtual health programs on AchievementTM, the largest digital health network in the United States.

The Track and Trace Solutions market was valued at US$ 1,728.3 million in 2018 and it is projected to reach US$ 6,049.0 million by 2027; it is expected to grow at a CAGR of 15.3% from 2018 to 2027.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.